Brugada Syndrome in the Emergency Department: High-Yield FRCEM SBA Practice Questions Explained

Brugada syndrome sits at the intersection of electrocardiography, inherited disease, and resuscitation medicine, making it a recurring and discriminating topic in FRCEM SBA practice questions. For the emergency physician, this condition demands prompt ECG recognition, accurate risk stratification, and the clinical confidence to act decisively when a patient presents with syncope, a resuscitated cardiac arrest, or an incidental ECG finding. This article works through the condition at the depth the FRCEM SBA exam expects, with structured revision material, practice question logic, and management anchored to current UK guidelines.

Clinical Context and Epidemiology

Brugada syndrome is an inherited primary electrical disorder of the myocardium. Structurally, the heart is normal. The danger lies entirely in the propensity for spontaneous ventricular fibrillation. It accounts for an estimated 4 to 12 percent of all sudden cardiac deaths globally and up to 20 percent of sudden deaths in individuals with structurally normal hearts, making it a genuinely important cause of preventable mortality in otherwise healthy young adults. The estimated general population prevalence is approximately 1 in 2,000, though this varies considerably by geography: South-East Asian populations carry a substantially higher burden, and the condition is recognised as a principal cause of sudden unexplained nocturnal death syndrome (SUNDS) in that region.

The condition follows an autosomal dominant inheritance pattern with variable penetrance. Approximately 20 to 30 percent of cases carry an identifiable loss-of-function mutation in SCN5A, the gene encoding the cardiac voltage-gated sodium channel Nav1.5. Over 400 additional mutations across more than 20 genes have been implicated, though a significant proportion of clinically confirmed cases remain genetically unexplained, which has important implications for counselling families. Male sex is one of the strongest clinical risk factors: men are 8 to 10 times more likely to experience symptomatic ventricular arrhythmias. This disparity is attributed in part to androgen-mediated upregulation of transient outward potassium current (Ito) and modulation of sodium channel expression. Peak clinical presentation occurs in the third and fourth decades of life.

From an exam standpoint, the Royal College of Emergency Medicine curriculum maps Brugada syndrome to the undifferentiated syncope and sudden cardiac death presentations that every emergency registrar must manage competently. The condition appears in FRCEM SBA exam questions precisely because it requires integrating ECG skills, pharmacological knowledge, and resuscitation decision-making within a single clinical scenario.

Pathophysiology: What the Exam Expects You to Know

Understanding the mechanism is not an optional extra in the FRCEM SBA exam. Questions frequently use pathophysiological detail to construct plausible distractors, and knowing the underlying science separates candidates who can reason from those who can only recall.

The fundamental abnormality is a reduction in inward sodium current (INa) during phase 0 of the cardiac action potential. In normal myocardium, phase 0 depolarisation is dominated by rapid sodium influx through Nav1.5 channels. In Brugada syndrome, this current is reduced. The consequence is unmasked by a heterogeneous distribution of the transient outward potassium current (Ito), which is particularly prominent in the right ventricular epicardium. With reduced INa opposing it, Ito produces an exaggerated phase 1 notch (the J point) in epicardial cells that does not occur in endocardial cells. This transmural voltage gradient manifests on the ECG as the characteristic ST elevation in the right precordial leads.

The arrhythmogenic mechanism arises from this same gradient. The epicardial action potential develops a prominent dome in normal conditions but loses this dome in Brugada syndrome, producing a steep dispersion of repolarisation across the right ventricular free wall. Phase 2 re-entry, a mechanism where the dome of one epicardial area triggers depolarisation in adjacent domeless areas, generates the substrate for ventricular premature beats that can initiate VF. Conditions that exacerbate this include fever (which further reduces sodium channel conductance), increased vagal tone (which augments Ito), and sodium channel-blocking drugs. This mechanistic understanding directly informs clinical management.

ED Assessment: History, ECG, and Investigations

History

The classic presentation is syncope or cardiac arrest in a young adult, often during sleep or at rest, with or without a family history of unexplained sudden death. Ask specifically about prior unexplained syncope, nocturnal seizure-like episodes (which may represent VF-related hypoxic events), and family history of sudden cardiac death in a first-degree relative under 45. Document all current and recent medications, and explicitly screen for sodium channel-blocking drugs, recreational drug use including cocaine, and recent febrile illness.

ECG Interpretation

This is the single most tested skill in FRCEM SBA practice questions relating to Brugada syndrome. Three ECG patterns are recognised:

• Type 1 (diagnostic coved pattern): ST elevation of at least 2 mm with a coved (convex or downsloping) morphology followed by a negative T wave in at least one of V1 or V2, recorded in a standard or high precordial position. This is the only pattern considered diagnostic.
• Type 2 (saddle-back pattern): ST elevation of at least 2 mm with a saddle-back morphology and a positive or biphasic T wave. This is not diagnostic without provocation testing or conversion to Type 1.
• Type 3: Saddle-back or coved pattern with ST elevation less than 2 mm. Non-diagnostic.

Critically, the ECG appearance is dynamic. A patient may have a diagnostic Type 1 pattern during fever but a non-diagnostic or normal ECG when well. This is a favourite exam pitfall. High precordial lead placement (V1 and V2 recorded at the second rather than the fourth intercostal space) increases sensitivity and should be documented when Brugada syndrome is suspected.

Investigations

Mandatory investigations in the ED include a 12-lead ECG with right precordial leads at standard and high positions, continuous cardiac monitoring, urea and electrolytes (hypokalaemia worsens the arrhythmic risk), blood glucose, and core temperature. If the patient is febrile, treat the fever actively. Request echocardiography to confirm structural normality before attribution of ECG changes to Brugada syndrome. Bloods for genetic testing are not an ED intervention but should be arranged as part of a coordinated inherited cardiac conditions (ICC) clinic referral.

Acute Management in the Emergency Department

Ventricular Fibrillation and Arrhythmia Storm

Immediate management of VF follows standard Resuscitation Council UK advanced life support algorithms: high-quality CPR, early defibrillation, and adrenaline according to the ALS protocol. The critical departure from standard ALS in Brugada syndrome is the management of arrhythmia storm (defined as three or more separate VF episodes within 24 hours, or continuously recurring VF). Intravenous isoproterenol (isoprenaline) is the treatment of choice for electrical storm in Brugada syndrome. It acts by increasing heart rate (which shortens the action potential and reduces the arrhythmogenic heterogeneity) and by reducing Ito. Quinidine, which blocks Ito, is an alternative agent used in specialist centres. Amiodarone is not effective in this context and should not be used as a first-line agent for arrhythmia storm specific to Brugada syndrome. This is a high-yield distinction for the FRCEM SBA exam.

Sodium Channel-Blocking Drugs: Contraindication and Provocation

Flecainide, ajmaline, procainamide, and other Class Ic and some Class Ia antiarrhythmics are contraindicated in known Brugada syndrome because they exacerbate sodium channel dysfunction and may precipitate lethal arrhythmia. The same mechanistic property is exploited diagnostically: pharmacological provocation with intravenous ajmaline or flecainide can unmask a Type 1 pattern in patients with Type 2 or normal ECGs. This provocation testing is performed exclusively in controlled inpatient or specialist settings, never in the ED. Candidates should recognise the distinction between the contraindicated therapeutic use and the controlled diagnostic use. The British National Formulary clearly flags the relevant contraindications for sodium channel-blocking antiarrhythmics.

Fever Management

In a febrile patient with known or suspected Brugada syndrome, fever is not merely a symptom to address for comfort. It is an active arrhythmic trigger. Aggressive antipyresis with paracetamol, tepid sponging, and treatment of the underlying infective cause must be initiated promptly. This principle appears frequently in clinical scenario-based FRCEM SBA exam questions.

Disposition

Any patient presenting with syncope or cardiac arrest and a confirmed or suspected Type 1 Brugada pattern requires urgent cardiology referral and inpatient admission for monitoring and further risk stratification. Asymptomatic patients with an incidental Type 1 pattern require non-urgent but expedited referral to an inherited cardiac conditions clinic. Patients with Type 2 patterns and a compelling clinical history warrant the same. No patient with a newly identified Brugada pattern should be discharged without a clear cardiology safety-net plan.

How the FRCEM SBA Exam Tests Brugada Syndrome

The FRCEM SBA exam uses Brugada syndrome to assess breadth across several curriculum domains simultaneously: ECG interpretation, pharmacological knowledge, resuscitation decision-making, and safe disposition. Common question formats include an ECG image with clinical vignette asking for the single best diagnostic interpretation, a clinical scenario of electrical storm asking for the most appropriate pharmacological intervention, a medication list asking which drug should be avoided in a patient with a known diagnosis, and a disposition question asking the appropriate action following an incidental Type 1 pattern in an asymptomatic patient attending for an unrelated complaint.

The RCEM curriculum explicitly expects trainees to recognise inherited arrhythmia syndromes, manage VF according to Resuscitation Council UK guidelines, and demonstrate safe referral practice. Candidates who prepare using high-quality FRCEM SBA practice questions in context, rather than isolated fact recall, consistently perform better on these scenario-based items.

Revision Pearls: High-Yield Facts for FRCEM SBA

1. Only the Type 1 coved ECG pattern is diagnostic of Brugada syndrome. Type 2 and Type 3 are not.
2. Brugada syndrome accounts for up to 20 percent of sudden cardiac deaths in structurally normal hearts.
3. Male sex confers an 8 to 10 times higher risk of symptomatic arrhythmia compared with female sex.
4. Fever is a reversible trigger; aggressive antipyresis is an active management intervention, not supportive care.
5. For arrhythmia storm, use intravenous isoproterenol (isoprenaline), not amiodarone.
6. Sodium channel blockers (flecainide, ajmaline, procainamide) are contraindicated therapeutically but are used diagnostically under controlled specialist conditions.
7. The only evidence-based long-term treatment for high-risk patients is an ICD. Quinidine (Ito blocker) is a pharmacological adjunct in selected patients.
8. Events characteristically cluster nocturnally and at rest, consistent with increased vagal tone.

Common Pitfalls: Where Candidates Lose Marks

• Confusing the Type 2 saddle-back pattern with a diagnostic finding and selecting management options appropriate only for confirmed Type 1.
• Choosing amiodarone for VF storm in Brugada syndrome rather than isoproterenol.
• Failing to recognise flecainide or another sodium channel blocker on a medication list as a contraindicated drug in this context.
• Discharging a patient with an incidentally identified Type 1 pattern without cardiology input because they are currently asymptomatic.
• Omitting fever treatment as part of the acute management, treating it as irrelevant to arrhythmia risk.
• Assuming a normal ECG in a well patient excludes Brugada syndrome in someone with a compelling history.

How EM Learning Centre Supports Your FRCEM Single Best Answer Revision

Brugada syndrome is one of dozens of inherited and acquired arrhythmia topics covered in depth at the EM Learning Centre. Our platform is built around the RCEM curriculum and delivers structured, evidence-based teaching at exactly the depth the FRCEM SBA exam requires. Each lesson integrates clinical context, pathophysiology, management algorithms, and worked FRCEM SBA practice questions so that you are not simply learning facts but learning to reason in the way the exam rewards.

If you are planning your exam preparation, our FRCEM Single Best Answer revision course at EM Learning Centre provides a comprehensive question bank, detailed explanations for every answer option, and curriculum-mapped learning objectives. Whether you are approaching the exam for the first time or seeking to push your score above the pass mark, targeted practice with high-quality clinical scenarios is the most evidence-consistent strategy for FRCEM SBA exam preparation. Explore the platform and see how structured MRCEM SBA revision and FRCEM SBA revision can be integrated into your working week without requiring a complete restructure of your schedule.

References

1. Royal College of Emergency Medicine. RCEM Curriculum and Credentials. rcem.ac.uk
2. Resuscitation Council UK. Advanced Life Support Guidelines 2025. resus.org.uk
3. British National Formulary. Antiarrhythmic drugs: contraindications and interactions. bnf.nice.org.uk
4. National Institute for Health and Care Excellence. Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure. nice.org.uk
5. The BMJ. Brugada syndrome: clinical features, diagnosis, and management. bmj.com